Placing Novel, Fixed-Dose Dual Bronchodilators within the nice Guidelines for Chronic Obstructive Pulmonary Disease -Reflections on the Past, Present and Future
Journal Title: Archives of Pulmonology and Respiratory Care - Year 2015, Vol 1, Issue 1
Abstract
The current National Institute for Health and Care Excellence (NICE) chronic obstructive pulmonary disease (COPD) guidelines were updated in 2010, reflecting clinical evidence available at that time. Since the guidelines were written, a growing body of evidence has demonstrated enhanced Bronchodilation with LABA/LAMA in fixed-dose combinations (FDCs) versus single component agents (the standard of care) in moderate to severe COPD. Studies to date indicate that the indacaterol/glycopyrronium (QVA149) and umeclinidium/vilanterol (UMEC/VI) can optimize Bronchodilation and may lead to improvements in patient-reported outcomes beyond lung function. The evidence for LABA/LAMA FDC, in particular glycopyrronium/indacaterol, and also umeclidinium/vilanterol, supported by meta-analysis, shows that dual Bronchodilation provides superior efficacy compared with LAMA monotherapy (glycopyrronium or tiotropium), and suggests the appropriateness of progression to LABA/LAMA combinations after LAMA mono therapy rather than escalation to LABA/ICS in patients with persistent breathlessness. The debate regarding the benefits and risks of LABA/ICS is on-going, with data now more firmly showing an association with inhaled ICS use and pneumonia. In patients with moderate or severe airflow obstruction and no history of exacerbations in the past year, randomised data showed that glycopyrronium/indacaterol was superior to LABA/ICS in improving lung function and breathlessness score. How to quantify the benefits of LABA/LAMA FDC over Mono therapy will be an ongoing debate, and consideration of other parameters such as a responder analysis of the proportion of patients that did achieve a threshold, may be better suited to establish clinically relevant differences between active agents and placebo. This review highlights the need to consider revisions to the current NICE COPD guidelines to reflect the recently published evidence demonstrating a role for LABA/LAMA FDC in the treatment of moderate to severe COPD.
Authors and Affiliations
O’Reilly John
Keywords
Related Articles
- EP ID EP340212
- DOI 10.17352/aprc.000001
- Views 86
- Downloads 0
Asthma Attacks During Pregnancy in the ICU: Just Be Alert
Background: Asthma represents one of the most common medical conditions encountered during pregnancy, which may seriously affect its outcome. Objective: To evaluate the outcome of asthma attacks during pregnancy and the...
A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre
A multidisciplinary team approach to diagnosis and management of interstitial lung diseases (ILD) is considered gold standard and an integral part of ILD management and guidelines. The accurate diagnosis and management o...
Ticarcillin Hypersusceptibility in Pseudomonas Aeruginosa in Cystic Fibrosis
Background: A subpopulation of Pseudomonas aeruginosa (PsA) exists in cystic fibrosis (CF) patients that is hypersusceptible to ticarcillin, a carboxypenicillin, in vitro (Tichs strain) defined as a minimum inhibitory co...
Usefulness of Transbronchial Cryobiopsy in Interstitial Lung Disease
Interstitial lung disease (ILD) is a term that describes a group of more than 200 lung disorders that show varying degrees of inflammation and fibrosis of the pulmonary interstitium. The etiology and pathophysiology of m...
Influence of the duration of noninvasive ventilation on the cardiorespiratory indicators of preterm infants: A randomized clinical trial
This study aimed to evaluate the cardiorespiratory indicators of preterm infants submitted to two noninvasive ventilator support systems in two periods. It was an controlled randomized clinical trial (RBR-7d9dth). Fifty-...